Bicara Therapeutics
Bicara Therapeutics develops first-in-class biologics that combine targeted therapies with tumor modulators, focusing on bifunctional antibodies like BCA101 to treat solid tumors.
Services
Bicara Therapeutics combines the precision of targeted therapies with the power of tumor modulators to develop first-in-class biologics. Their cutting-edge bifunctional antibodies deliver an immunomodulatory payload directly to the tumor microenvironment, enhancing immune cell activity and targeting solid tumors. The company focuses on transforming patient care through these innovative therapies, aiming to significantly impact cancer treatment outcomes.
Products
Bicara Therapeutics' lead product, BCA101, is a first-in-class EGFR / TGF-β-trap bifunctional antibody. Currently, BCA101 is in Phase 1/1b clinical trials, assessing its effectiveness as a standalone treatment and in combination with pembrolizumab for various solid tumors, including unresectable, recurrent, or metastatic HNSCC. The company's pipeline also includes additional bifunctional antibodies and biologics designed to treat solid tumors.
Clinical Trials
Bicara Therapeutics is actively enrolling patients in clinical trials for their lead asset, BCA101. The trials are being conducted in multiple locations, including Houston, TX; New York, NY; Boston, MA; Toronto, ON; Pittsburgh, PA; Charleston, SC; Los Angeles, CA; San Diego, CA; Tampa, FL; Cleveland, OH; and Providence, RI. Dose escalation studies for BCA101 have been completed, evaluating its effects both as a single-agent and in combination with pembrolizumab.
Research and Development
The research and development efforts at Bicara Therapeutics are focused on creating bifunctional antibodies that can effectively deliver immunomodulatory payloads directly to tumors. Their flagship product, BCA101, inhibits tumor growth and modulates the tumor microenvironment by targeting both EGFR and TGF-β. This results in enhanced anti-tumor efficacy and an improved therapeutic window, minimizing side effects by reducing AKT activation and derepressing ADCC function.
Corporate Culture
Bicara Therapeutics is dedicated to building diverse teams and fostering an inclusive culture where every voice is heard. Their commitment to diversity and inclusion is integral to their mission of advancing cancer treatment and improving patient outcomes. The company encourages collaborative efforts and values the unique contributions of all team members in their shared goal of transforming patient care.